Immune cell trafficking to the islets during type 1 diabetes | Zendy

Sandor A. M. | Zendy; Jacobelli J. | Zendy; Friedman R. S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune cell trafficking to the islets during type 1 diabetes

Author(s) -

Sandor A. M.,

Jacobelli J.,

Friedman R. S.

Publication year - 2019

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13353

Subject(s) - immune system , pancreatic islets , chemokine , islet , type 1 diabetes , immunology , microbiology and biotechnology , cell , t cell , cell type , biology , medicine , insulin , diabetes mellitus , endocrinology , genetics

Summary Inhibition of immune cell trafficking to the pancreatic islets during type 1 diabetes (T1D) has therapeutic potential, since targeting of T cell and B cell trafficking has been clinically effective in other autoimmune diseases. Trafficking to the islets is characterized by redundancy in adhesion molecule and chemokine usage, which has not enabled effective targeting to date. Additionally, cognate antigen is not consistently required for T cell entry into the islets throughout the progression of disease. However, myeloid cells are required to enable T cell and B cell entry into the islets, and may serve as a convergence point in the pathways controlling this process. In this review we describe current knowledge of the factors that mediate immune cell trafficking to pancreatic islets during T1D progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research